Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Vaccine for Killer Disease One Step Closer

Published: Monday, November 19, 2012
Last Updated: Sunday, November 18, 2012
Bookmark and Share
New 4CMenB vaccine designed to cover most strains of the disease in Europe.

Leading meningitis charity Meningitis Research Foundation (MRF) has welcomed the news that a potentially lifesaving vaccine to prevent MenB is one step closer with positive opinion by the European Medicines Agency (EMA).

The vaccine, 4CMenB produced by Novartis Vaccines and Diagnostics Limited is the first ever vaccine against meningococcal B meningitis and septicaemia (MenB) designed to cover most strains of the disease in Europe.

MenB is responsible for an average of 1870 cases across the UK each year, mostly in young children.

Around 1 in 10 people affected will die, and a further 1 in 10 survivors will be left with serious after-effects, such as limb amputations, deafness, blindness, and brain damage.

The new vaccine will require a license from the European Commission before European governments can consider it for implementation.

The UK Government takes vaccination advice from the Joint Committee on Vaccination and Immunization.

If they recommend the new MenB vaccine, the earliest it could be implemented in the UK would be the end of 2013.

Chris Head, Chief Executive of Meningitis Research Foundation said: “We have a vision of a world free from meningitis and septicaemia so this news is a huge boost for our members and their families, and for doctors and scientists who have all worked tirelessly against this devastating disease. Since the first meningitis vaccine was introduced in 1992, many strains of meningitis including Hib, MenC and pneumococcal have been dramatically reduced. Once the MenB vaccine is licensed, it is essential that Government give it full consideration as soon as possible, especially given the shocking lifetime costs to people who survive MenB and are left with serious, life-long disabilities. We must not allow children to die from this disease if it can be prevented.”

MRF Trustee Professor George Griffin, professor of Infectious Diseases and Medicine at St George’s University of London said: “This vaccine is a real step forward and will have a major impact on MenB cases. However, meningitis will remain a major clinical problem and research into microbial causes continues to be a priority alongside raising public awareness of the symptoms.”

Paralympics reporter and keen equestrian Diana Man (30) from Tunbridge Wells is building a new life after contracting MenB in November 2007 which left her without her lower legs, her fingers and with epilepsy.

She said: “My life has changed a great deal since getting MenB, but I have learned to adjust and manage just like anyone else. If a vaccine has been produced to prevent this disease it should be made available as soon as possible to prevent anyone else having to face the difficulties myself and others face in the future both physically, emotionally and financially.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Developing a More Precise Seasonal Flu Vaccine
During the 2014-15 flu season, the poor match between the virus used to make the world’s vaccine stocks and the circulating seasonal virus yielded a vaccine that was less than 20 percent effective.
Fighting Cancer with Borrowed Immunity
A new step in cancer immunotherapy: researchers from the Netherlands Cancer Institute and University of Oslo/Oslo University Hospital show that even if one's own immune cells cannot recognize and fight their tumors, someone else's immune cells might.
Modified Microalgae Converts Sunlight into Valuable Medicine
A special type of microalgae can soon produce valuable chemicals such as cancer treatment drugs and much more just by harnessing energy from the sun.
Immune Cells Remember Their First Meal
Scientists at the University of Bristol have identified the trigger for immune cells' inflammatory response – a discovery that may pave the way for new treatments for many human diseases.
Paper Filter Can Remove Viruses from Water
A new paper filter can purify water from viruses, even the most difficult and contagious.
Large-scale HIV Vaccine Trial to Launch in South Africa
NIH-funded study will test safety, efficacy of vaccine regimen.
New HIV Vaccine Target Discovered
NIH-Led team have discovered a new vaccine target site on HIV.
Mimicking Evolution to Create Novel Proteins
A study by researchers in the Kuhlman lab offers a new route to design the 'cellular machines' needed to understand and battle diseases.
Antibody Therapy Opens Door to Potential New Treatment for HIV
Researchers at Rockefeller University show how a broadly neutralizing antibody could be used to help fight HIV.
Investigational Malaria Vaccine Protects Healthy U.S. Adults
Researchers at NIH have found that the malaria vaccine protected a small number of healthy, malaria-naïve adults in the U.S. from infection for more than one year after immunization.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!